Shares Outstanding Shares Outstanding n/a Close	61.51M
Shares Change (YoY) Shares Change (YoY) n/a Close	0.59%
Shares Change (QoQ) Shares Change (QoQ) n/a Close	0.12%
Owned by Institutions (%) Owned by Institutions (%) n/a Close	74.37%
Shares Floating Shares Floating n/a Close	45.99M
Failed to Deliver (FTD) Shares Failed to Deliver (FTD) Shares n/a Close	49
FTD / Avg. Volume FTD / Avg. Volume n/a Close	0.01%

Short Selling Information

The latest short interest is 8.08M, so 13.13% of the outstanding shares have been sold short.

Short Interest Short Interest n/a Close	8.08M
Short % of Shares Out Short % of Shares Out n/a Close	13.13%
Short % of Float Short % of Float n/a Close	17.41%
Short Ratio (days to cover) Short Ratio (days to cover) n/a Close	16.44

Valuation Ratios

The PE ratio is -7.06 and the forward PE ratio is -3.41. Monte Rosa Therapeutics's PEG ratio is 0.11.

PE Ratio PE Ratio n/a Close	-7.06
Forward PE Forward PE n/a Close	-3.41
PS Ratio PS Ratio n/a Close	6.78
Forward PS Forward PS n/a Close	2.5
PB Ratio PB Ratio n/a Close	2.3
P/FCF Ratio P/FCF Ratio n/a Close	13.5
PEG Ratio PEG Ratio n/a Close	0.11

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Monte Rosa Therapeutics.

EV / Sales EV / Sales n/a Close	n/a
EV / EBITDA EV / EBITDA n/a Close	n/a
EV / EBIT EV / EBIT n/a Close	n/a
EV / FCF EV / FCF n/a Close	n/a

Financial Position

The company has a current ratio of 2.4, with a Debt / Equity ratio of 0.19.

Current Ratio Current Ratio n/a Close	2.4
Quick Ratio Quick Ratio n/a Close	2.4
Debt / Equity Debt / Equity n/a Close	0.19
Debt / EBITDA Debt / EBITDA n/a Close	-0.59
Debt / FCF Debt / FCF n/a Close	1.12
Interest Coverage Interest Coverage n/a Close	0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity Return on Equity n/a Close	n/a
Return on Assets Return on Assets n/a Close	n/a
Return on Invested Capital Return on Invested Capital n/a Close	n/a
Revenue Per Employee Revenue Per Employee n/a Close	$532,549.3
Profits Per Employee Profits Per Employee n/a Close	$-511,971.83
Employee Count Employee Count n/a Close	142
Asset Turnover Asset Turnover n/a Close	0.17
Inventory Turnover Inventory Turnover n/a Close	n/a

Taxes

Income Tax Income Tax n/a Close	2.57M
Effective Tax Rate Effective Tax Rate n/a Close	-3.66%

Stock Price Statistics

The stock price has increased by 31.34% in the last 52 weeks. The beta is 1.4, so Monte Rosa Therapeutics's price volatility has been higher than the market average.

Beta Beta n/a Close	1.4
52-Week Price Change 52-Week Price Change n/a Close	31.34%
50-Day Moving Average 50-Day Moving Average n/a Close	4.44
200-Day Moving Average 200-Day Moving Average n/a Close	6.09
Relative Strength Index (RSI) Relative Strength Index (RSI) n/a Close	56.46
Average Volume (20 Days) Average Volume (20 Days) n/a Close	667,979

Income Statement

In the last 12 months, Monte Rosa Therapeutics had revenue of 75.62M and earned -72.7M in profits. Earnings per share was -0.98.

Revenue Revenue n/a Close	75.62M
Gross Profit Gross Profit n/a Close	67.5M
Operating Income Operating Income n/a Close	-81.11M
Net Income Net Income n/a Close	-72.7M
EBITDA EBITDA n/a Close	-72.99M
EBIT EBIT n/a Close	-81.11M
Earnings Per Share (EPS) Earnings Per Share (EPS) n/a Close	-0.98

Full Income Statement

Balance Sheet

The company has 224.25M in cash and 42.72M in debt, giving a net cash position of 181.54M.

Cash & Cash Equivalents Cash & Cash Equivalents n/a Close	224.25M
Total Debt Total Debt n/a Close	42.72M
Net Cash Net Cash n/a Close	181.54M
Retained Earnings Retained Earnings n/a Close	-438.59M
Total Assets Total Assets n/a Close	393.2M
Working Capital Working Capital n/a Close	273.06M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 42M and capital expenditures -3.99M, giving a free cash flow of 38.01M.

Operating Cash Flow Operating Cash Flow n/a Close	42M
Capital Expenditures Capital Expenditures n/a Close	-3.99M
Free Cash Flow Free Cash Flow n/a Close	38.01M
FCF Per Share FCF Per Share n/a Close	0.51

Full Cash Flow Statement

Margins

Gross margin is 89.26%, with operating and profit margins of -107.26% and -96.14%.

Gross Margin Gross Margin n/a Close	89.26%
Operating Margin Operating Margin n/a Close	-107.26%
Pretax Margin Pretax Margin n/a Close	-92.74%
Profit Margin Profit Margin n/a Close	-96.14%
EBITDA Margin EBITDA Margin n/a Close	-96.52%
EBIT Margin EBIT Margin n/a Close	-107.26%
FCF Margin FCF Margin n/a Close	50.26%

Dividends & Yields

GLUE does not appear to pay any dividends at this time.

Dividend Per Share Dividend Per Share n/a Close	n/a
Dividend Yield Dividend Yield n/a Close	n/a
Dividend Growth (YoY) Dividend Growth (YoY) n/a Close	n/a
Payout Ratio Payout Ratio n/a Close	n/a
Earnings Yield Earnings Yield n/a Close	n/a
FCF Yield FCF Yield n/a Close	n/a

Dividend Details

Analyst Forecast

The average price target for GLUE is $16, which is 232% higher than the current price. The consensus rating is "Buy".

Price Target Price Target n/a Close	$16
Price Target Difference Price Target Difference n/a Close	232%
Analyst Consensus Analyst Consensus n/a Close	Buy
Analyst Count Analyst Count n/a Close	3

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value Lynch Fair Value n/a Close	n/a
Lynch Upside Lynch Upside n/a Close	n/a
Graham Number Graham Number n/a Close	n/a
Graham Upside Graham Upside n/a Close	n/a

Scores

Altman Z-Score Altman Z-Score n/a Close	1.1
Piotroski F-Score Piotroski F-Score n/a Close	7